Free Trial
Leerink Partners

Leerink Partners Analyst Recommendations & Stock Picks

View the latest stock recommendations issued by analysts at Leerink Partners. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Leerink Partners' equity research team. MarketBeat is not affiliated with or endorsed by Leerink Partners.

Average Return
00.00% 12-Month ROI
Total Ratings
378 Last 12 Months
Buy Ratings
245 Last 12 Months
Sell Ratings
5 Last 12 Months
Companies Covered
205 Last 12 Months
MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetails
Icon Plc stock logo
ICLR
Icon
$136.07
-0.5%
5/28/2026Set Price Target$145.00View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/28/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$48.32
-1.6%
5/28/2026Lower Price Target$87.00 ➝ $74.00OutperformView details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 5/28/2026
Equillium, Inc. stock logo
EQ
Equillium
$2.90
+2.1%
5/28/2026Upgrade$1.00 ➝ $6.00Market PerformOutperformView details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 5/28/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,105.37
-1.9%
5/26/2026Set Price Target$1,119.00View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 5/26/2026
Seaport Therapeutics, Inc. stock logo
SPTX
Seaport Therapeutics
$18.19
-3.2%
5/26/2026Initiated Coverage$35.00OutperformView details for Leerink Partners rating of Seaport Therapeutics (NASDAQ:SPTX) on 5/26/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$66.87
-3.1%
5/22/2026Set Price Target$80.00View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/22/2026
Encompass Health Corporation stock logo
EHC
Encompass Health
$105.98
+0.6%
5/22/2026Set Price Target$152.00View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 5/22/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.99
+0.4%
5/21/2026Set Price Target$42.00View details for Leerink Partners rating of Roivant Sciences (NASDAQ:ROIV) on 5/21/2026
Compugen Ltd. stock logo
CGEN
Compugen
$2.63
-5.4%
5/21/2026 Lower Price Target$13.00 ➝ $5.00OutperformView details for Leerink Partners rating of Compugen (NASDAQ:CGEN) on 5/21/2026
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$4.36
+3.7%
5/21/2026Initiated Coverage$10.00OutperformView details for Leerink Partners rating of Opus Genetics (NASDAQ:IRD) on 5/21/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$614.78
-1.1%
5/18/2026Reiterated Rating$792.00 ➝ $641.00OutperformMarket PerformView details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/18/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$287.92
-0.9%
5/15/2026 Boost Price Target$364.00 ➝ $367.00OutperformView details for Leerink Partners rating of BeOne Medicines (NASDAQ:ONC) on 5/15/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$55.67
-2.4%
5/15/2026Set Price Target$90.00View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 5/15/2026
Immunome, Inc. stock logo
IMNM
Immunome
$21.83
-3.1%
5/15/2026Lower Price Target$37.00 ➝ $33.00OutperformView details for Leerink Partners rating of Immunome (NASDAQ:IMNM) on 5/15/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$29.23
-1.3%
5/15/2026 Set Price Target$38.00 ➝ $43.00OutperformView details for Leerink Partners rating of Sutro Biopharma (NASDAQ:STRO) on 5/15/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$13.00
-2.7%
5/15/2026Initiated CoverageOutperformView details for Leerink Partners rating of Avidity Biosciences (NASDAQ:RNA) on 5/15/2026
Doximity, Inc. stock logo
DOCS
Doximity
$21.35
+1.3%
5/14/2026Lower Price Target$31.00 ➝ $25.00OutperformView details for Leerink Partners rating of Doximity (NYSE:DOCS) on 5/14/2026
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
$5.38
-2.9%
5/14/2026 Set Price Target$4.50View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2026
Anthem, Inc. stock logo
ANTX
Anthem
$4.33
-2.9%
5/14/2026Upgrade$9.00Market PerformOutperformView details for Leerink Partners rating of Anthem (NASDAQ:ANTX) on 5/14/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$21.98
+9.9%
5/14/2026Boost Price Target$28.00 ➝ $55.00OutperformView details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 5/14/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$225.16
-2.4%
5/13/2026Upgrade$265.00Market PerformOutperformView details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 5/13/2026
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$7.47
-0.4%
5/12/2026 Set Price Target$17.00View details for Leerink Partners rating of Aura Biosciences (NASDAQ:AURA) on 5/12/2026
ALMR
Alamar Biosciences
$20.44
+3.4%
5/12/2026Initiated Coverage$35.00OutperformView details for Leerink Partners rating of Alamar Biosciences (NASDAQ:ALMR) on 5/12/2026
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
$22.99
+0.2%
5/12/2026Initiated Coverage$36.00OutperformView details for Leerink Partners rating of Kailera Therapeutics (NASDAQ:KLRA) on 5/12/2026
enGene Holdings Inc. stock logo
ENGN
enGene
$1.85
+3.9%
5/8/2026 Downgrade$2.00OutperformMarket PerformView details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 5/8/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$134.43
-1.3%
5/8/2026 Lower Price Target$148.00 ➝ $146.00View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 5/8/2026
Insulet Corporation stock logo
PODD
Insulet
$144.94
+1.6%
5/7/2026 Lower Price Target$360.00 ➝ $247.00View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 5/7/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$66.87
-3.1%
5/5/2026Upgrade$70.00Market PerformOutperformView details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/5/2026
Icon Plc stock logo
ICLR
Icon
$136.07
-0.5%
5/4/2026Set Price Target$125.00View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/4/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$58.53
+0.9%
4/30/2026Set Price Target$120.00View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 4/30/2026
Align Technology, Inc. stock logo
ALGN
Align Technology
$174.95
+1.0%
4/30/2026 Boost Price Target$225.00 ➝ $230.00View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 4/30/2026
Humana Inc. stock logo
HUM
Humana
$305.97
-0.9%
4/30/2026 Boost Price Target$185.00 ➝ $255.00Market PerformView details for Leerink Partners rating of Humana (NYSE:HUM) on 4/30/2026
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
$26.85
+0.3%
4/29/2026 DowngradeStrong-BuyHoldView details for Leerink Partners rating of KalVista Pharmaceuticals (NASDAQ:KALV) on 4/29/2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$10.52
+3.2%
4/29/2026Upgrade$12.00 ➝ $25.00Market PerformOutperformView details for Leerink Partners rating of NeoGenomics (NASDAQ:NEO) on 4/29/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$55.67
-2.4%
4/28/2026Boost Price Target$66.00 ➝ $85.00OutperformView details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 4/28/2026
CorMedix Inc stock logo
CRMD
CorMedix
$8.44
+0.2%
4/28/2026Boost Price Target$13.00 ➝ $14.00OutperformView details for Leerink Partners rating of CorMedix (NASDAQ:CRMD) on 4/28/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$14.07
+2.9%
4/27/2026 Set Price Target$35.00View details for Leerink Partners rating of Intellia Therapeutics (NASDAQ:NTLA) on 4/27/2026
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$377.72
-1.7%
4/27/2026 Lower Price Target$573.00 ➝ $500.00OutperformView details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 4/27/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,105.37
-1.9%
4/27/2026 Lower Price Target$1,296.00 ➝ $1,058.00OutperformView details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 4/27/2026
TRAX
First Tracks Biotherapeutics
$15.96
+0.9%
4/24/2026Initiated Coverage$46.00OutperformView details for Leerink Partners rating of First Tracks Biotherapeutics (NASDAQ:TRAX) on 4/24/2026
Before you buy SpaceX shares, consider this alternative approach (Ad)

SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel

Discover the overlooked SpaceX IPO strategy before the June listing
Elevance Health, Inc. stock logo
ELV
Elevance Health
$394.40
+0.4%
4/23/2026 Set Price Target$364.00View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 4/23/2026
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$12.12
+0.2%
4/22/2026Lower Price Target$25.00 ➝ $24.00OutperformView details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 4/22/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
$24.19
+3.0%
4/22/2026Boost Price Target$23.00 ➝ $30.00OutperformView details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 4/22/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$21.04
+0.4%
4/22/2026Lower Price Target$40.00 ➝ $35.00OutperformView details for Leerink Partners rating of Denali Therapeutics (NASDAQ:DNLI) on 4/22/2026
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$424.59
+0.2%
4/22/2026Lower Price Target$622.00 ➝ $573.00OutperformView details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 4/22/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$236.49
+0.5%
4/22/2026Boost Price Target$215.00 ➝ $225.00OutperformView details for Leerink Partners rating of Jazz Pharmaceuticals (NASDAQ:JAZZ) on 4/22/2026
MANE
MANE
$101.01
-1.8%
4/22/2026Boost Price Target$75.00 ➝ $90.00OutperformView details for Leerink Partners rating of MANE (NYSE:MANE) on 4/22/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$158.30
+1.2%
4/22/2026Boost Price Target$160.00 ➝ $170.00OutperformView details for Leerink Partners rating of Neurocrine Biosciences (NASDAQ:NBIX) on 4/22/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$379.70
-0.7%
4/22/2026Boost Price Target$345.00 ➝ $400.00OutperformView details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 4/22/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$85.36
-1.1%
4/21/2026 Lower Price Target$119.00 ➝ $106.00Market PerformView details for Leerink Partners rating of Abbott Laboratories (NYSE:ABT) on 4/21/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$25.32
+3.4%
4/20/2026 Set Price Target$47.00View details for Leerink Partners rating of Arcus Biosciences (NYSE:RCUS) on 4/20/2026
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
$21.14
+20.2%
4/20/2026 Initiated Coverage$50.00OutperformView details for Leerink Partners rating of Sensei Biotherapeutics (NASDAQ:SNSE) on 4/20/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$225.16
-2.4%
4/15/2026 Boost Price Target$232.00 ➝ $252.00Market PerformView details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 4/15/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
$8.69
+85.7%
4/13/2026Reiterated Rating$11.00 ➝ $2.00OutperformMarket PerformView details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 4/13/2026
Stryker Corporation stock logo
SYK
Stryker
$305.73
-0.6%
4/13/2026Initiated Coverage$410.00OutperformView details for Leerink Partners rating of Stryker (NYSE:SYK) on 4/13/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$73.50
+1.9%
4/13/2026Boost Price Target$49.00 ➝ $106.00OutperformView details for Leerink Partners rating of Spyre Therapeutics (NASDAQ:SYRE) on 4/13/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$82.46
-0.4%
4/13/2026Initiated Coverage$101.00HoldView details for Leerink Partners rating of Zimmer Biomet (NYSE:ZBH) on 4/13/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$29.23
-1.3%
4/7/2026 Initiated Coverage$38.00OutperformView details for Leerink Partners rating of Sutro Biopharma (NASDAQ:STRO) on 4/7/2026
MSLE
Satellos Bioscience
$7.30
+3.8%
4/6/2026Initiated Coverage$20.00OutperformView details for Leerink Partners rating of Satellos Bioscience (NASDAQ:MSLE) on 4/6/2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
$4.39
-2.2%
4/2/2026Boost Price Target$8.00 ➝ $9.00OutperformView details for Leerink Partners rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 4/2/2026
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$39.76
-0.1%
4/1/2026Downgrade$36.00 ➝ $40.00OutperformHoldView details for Leerink Partners rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 4/1/2026
Insmed, Inc. stock logo
INSM
Insmed
$106.91
-1.3%
3/24/2026Boost Price Target$210.00 ➝ $215.00OutperformView details for Leerink Partners rating of Insmed (NASDAQ:INSM) on 3/24/2026
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
$11.94
+5.7%
3/20/2026 Initiated Coverage$23.00OutperformView details for Leerink Partners rating of Adlai Nortye (NASDAQ:ANL) on 3/20/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$99.56
-0.8%
3/19/2026Boost Price Target$107.00 ➝ $110.00OutperformView details for Leerink Partners rating of Protagonist Therapeutics (NASDAQ:PTGX) on 3/19/2026
BrightSpring Health Services, Inc. stock logo
BTSG
BrightSpring Health Services
$61.68
+1.4%
3/18/2026Reiterated Rating$49.00OutperformView details for Leerink Partners rating of BrightSpring Health Services (NASDAQ:BTSG) on 3/18/2026
Cencora, Inc. stock logo
COR
Cencora
$269.21
+0.6%
3/17/2026 Reiterated RatingOutperformView details for Leerink Partners rating of Cencora (NYSE:COR) on 3/17/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$39.34
-2.1%
3/16/2026 Reiterated RatingOutperformView details for Leerink Partners rating of Structure Therapeutics (NASDAQ:GPCR) on 3/16/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$26.12
+2.9%
3/16/2026Boost Price Target$17.50 ➝ $25.00Market PerformView details for Leerink Partners rating of Hims & Hers Health (NYSE:HIMS) on 3/16/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$58.53
+0.9%
3/16/2026Boost Price Target$58.00 ➝ $86.00OutperformView details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 3/16/2026
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$2.45
+2.9%
3/13/2026Set Price Target$2.00Market PerformView details for Leerink Partners rating of Century Therapeutics (NASDAQ:IPSC) on 3/13/2026
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$6.04
-3.4%
3/12/2026 Reiterated RatingOutperformView details for Leerink Partners rating of Ardelyx (NASDAQ:ARDX) on 3/12/2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$0.87
+8.8%
3/12/2026Reiterated Rating$2.00OutperformView details for Leerink Partners rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/12/2026
Rivian Automotive, Inc. stock logo
RIVN
Rivian Automotive
$16.30
+7.2%
3/12/2026 Reiterated RatingOutperformView details for Leerink Partners rating of Rivian Automotive (NASDAQ:RIVN) on 3/12/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.26
-3.2%
3/12/2026Reiterated Rating$98.00OutperformView details for Leerink Partners rating of BridgeBio Pharma (NASDAQ:BBIO) on 3/12/2026
Vericel Corporation stock logo
VCEL
Vericel
$33.33
-2.7%
3/10/2026Reiterated Rating$46.00OutperformView details for Leerink Partners rating of Vericel (NASDAQ:VCEL) on 3/10/2026
Zoetis Inc. stock logo
ZTS
Zoetis
$77.81
-0.6%
3/10/2026 Reiterated RatingMarket PerformView details for Leerink Partners rating of Zoetis (NYSE:ZTS) on 3/10/2026
Medtronic PLC stock logo
MDT
Medtronic
$73.73
-2.4%
3/10/2026Reiterated Rating$119.00OutperformView details for Leerink Partners rating of Medtronic (NYSE:MDT) on 3/10/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$76.76
-0.1%
3/10/2026Reiterated RatingOutperformView details for Leerink Partners rating of Cytokinetics (NASDAQ:CYTK) on 3/10/2026
3D Systems Corporation stock logo
DDD
3D Systems
$3.55
+1.4%
3/10/2026 Reiterated RatingOutperformView details for Leerink Partners rating of 3D Systems (NYSE:DDD) on 3/10/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$9.07
-3.5%
3/10/2026Set Price Target$26.00OutperformView details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/10/2026
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$196.57
-1.6%
3/9/2026Reiterated Rating$275.00OutperformView details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 3/9/2026
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$76.58
+0.3%
3/9/2026Reiterated RatingMarket PerformView details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 3/9/2026
CorMedix Inc stock logo
CRMD
CorMedix
$8.44
+0.2%
3/6/2026Reiterated Rating$13.00OutperformView details for Leerink Partners rating of CorMedix (NASDAQ:CRMD) on 3/6/2026
Ardent Health, Inc. stock logo
ARDT
Ardent Health
$9.21
-2.7%
3/6/2026Lower Price Target$16.00 ➝ $15.00OutperformView details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 3/6/2026
Amgen Inc. stock logo
AMGN
Amgen
$336.79
+0.1%
3/5/2026Reiterated Rating$355.00Market PerformView details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 3/5/2026
CVS Health Corporation stock logo
CVS
CVS Health
$90.97
-2.2%
3/5/2026Reiterated Rating$98.00OutperformView details for Leerink Partners rating of CVS Health (NYSE:CVS) on 3/5/2026
McKesson Corporation stock logo
MCK
McKesson
$741.47
-2.0%
3/5/2026Reiterated Rating$1,085.00OutperformView details for Leerink Partners rating of McKesson (NYSE:MCK) on 3/5/2026
Clover Health Investments, Corp. stock logo
CLOV
Clover Health Investments
$3.98
-4.8%
3/5/2026Lower Price Target$3.00 ➝ $2.50Market PerformView details for Leerink Partners rating of Clover Health Investments (NASDAQ:CLOV) on 3/5/2026
Biohaven Ltd. stock logo
BHVN
Biohaven
$11.02
+7.6%
3/3/2026Reiterated Rating$15.00OutperformView details for Leerink Partners rating of Biohaven (NYSE:BHVN) on 3/3/2026
Spyglass Pharma, Inc. stock logo
SGP
Spyglass Pharma
$19.26
-2.9%
3/3/2026 DowngradeMarket PerformView details for Leerink Partners rating of Spyglass Pharma (NASDAQ:SGP) on 3/3/2026
Before you buy SpaceX shares, consider this alternative approach (Ad)

SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel

Discover the overlooked SpaceX IPO strategy before the June listing
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
$11.25
-2.5%
3/3/2026Initiated Coverage$36.00OutperformView details for Leerink Partners rating of AgomAb Therapeutics (NASDAQ:AGMB) on 3/3/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$76.50
-1.1%
3/3/2026Boost Price Target$102.00 ➝ $104.00OutperformView details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 3/3/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$14.07
+2.9%
3/3/2026Boost Price Target$27.00 ➝ $29.00OutperformView details for Leerink Partners rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/3/2026
Spyglass Pharma, Inc. stock logo
SGP
Spyglass Pharma
$19.26
-2.9%
3/3/2026Initiated Coverage$42.00OutperformView details for Leerink Partners rating of Spyglass Pharma (NASDAQ:SGP) on 3/3/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
$25.13
-1.4%
3/3/2026Boost Price Target$52.00 ➝ $58.00OutperformView details for Leerink Partners rating of Zymeworks (NASDAQ:ZYME) on 3/3/2026
uniQure N.V. stock logo
QURE
uniQure
$28.53
+14.8%
3/2/2026Reiterated Rating$35.00OutperformView details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 3/2/2026
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$196.57
-1.6%
3/2/2026Boost Price Target$268.00 ➝ $275.00OutperformView details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 3/2/2026
MANE
MANE
$101.01
-1.8%
3/2/2026Initiated Coverage$75.00OutperformView details for Leerink Partners rating of MANE (NYSE:MANE) on 3/2/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$25.32
+3.4%
3/2/2026Boost Price Target$36.00 ➝ $49.00OutperformView details for Leerink Partners rating of Arcus Biosciences (NYSE:RCUS) on 3/2/2026
Certara, Inc. stock logo
CERT
Certara
$5.82
+2.6%
2/26/2026Reiterated Rating$10.00OutperformView details for Leerink Partners rating of Certara (NASDAQ:CERT) on 2/26/2026

MarketBeat's community ratings are surveys of what our community members think about Leerink Partners and other research firms in the last 90 days. Vote "Outperform" if you believe Leerink Partners's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Leerink Partners's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.
COMMUNITY RATINGS
2.6out of 5 (last 90 days)
2.6 of 5 stars
OUTPERFORM VOTES
26 Believe will outperform the market
UNDERPERFORM VOTES
24 Believe will underperform the market

Leerink Partners' equity research team has issued ratings on 203 companies across 9 sectors over the past 12 months, covered by 19 analysts. The Leerink Partners analysts below are listed by number of ratings issued in the last year.

Leerink Partners Stock Coverage by Sector

Leerink Partners concentrates its research most heavily in Medical (89.8%), Manufacturing (5.9%) and Services (0.5%). The chart below shows how Leerink Partners' 205 rated companies are distributed across all 9 sectors it covers.

Leerink Partners - Frequently Asked Questions

Leerink Partners' analysts currently have buy-equivalent ratings on 157 companies. Recent upgrades to buy include Equillium, Anthem, Johnson & Johnson, Twist Bioscience and NeoGenomics.

Leerink Partners' highest-rated analysts by MarketBeat's accuracy score include Andrew Berens, Joseph Schwartz and Whit Mayo. Rankings are based on historical rating accuracy and price target precision over the past 12 months. MarketBeat tracks 19 analysts at Leerink Partners.

Leerink Partners has the deepest coverage in Medical (89.8% of rated companies), Manufacturing (5.9% of rated companies), Industrials (0.5% of rated companies), Finance (0.5% of rated companies) and Computer and Technology (0.5% of rated companies).

Leerink Partners issued 378 ratings over the last 12 months across 205 companies — an average of roughly 32 rating actions per month. These include boost price target, downgrade, initiated coverage, lower price target, reiterated rating, set price target and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current Leerink Partners analyst actions.

A buy rating indicates the analyst expects the stock to outperform the market over the next 12 months. A hold suggests the stock will perform in line with the market. A sell rating indicates expected underperformance. Leerink Partners uses Outperform, Market Perform, and Underperform as their equivalents.